GILD
Price
$115.76
Change
-$0.12 (-0.10%)
Updated
Sep 9, 04:59 PM (EDT)
Capitalization
143.64B
43 days until earnings call
PFE
Price
$24.71
Change
+$0.16 (+0.65%)
Updated
Sep 9 closing price
Capitalization
140.49B
55 days until earnings call
Interact to see
Advertisement

GILD vs PFE

Header iconGILD vs PFE Comparison
Open Charts GILD vs PFEBanner chart's image
Gilead Sciences
Price$115.76
Change-$0.12 (-0.10%)
Volume$84.52K
Capitalization143.64B
Pfizer
Price$24.71
Change+$0.16 (+0.65%)
Volume$32.75M
Capitalization140.49B
GILD vs PFE Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. PFE commentary
Sep 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Buy and PFE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2025
Stock price -- (GILD: $115.76 vs. PFE: $24.71)
Brand notoriety: GILD and PFE are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 86% vs. PFE: 79%
Market capitalization -- GILD: $143.64B vs. PFE: $140.49B
GILD [@Pharmaceuticals: Major] is valued at $143.64B. PFE’s [@Pharmaceuticals: Major] market capitalization is $140.49B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $672.89B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • GILD’s FA Score: 3 green, 2 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, GILD is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 5 bullish, 3 bearish.
  • PFE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GILD is a better buy in the short-term than PFE.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а +2.71% price change this week, while PFE (@Pharmaceuticals: Major) price change was -1.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.10%. For the same industry, the average monthly price growth was +4.65%, and the average quarterly price growth was +13.54%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.10% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($144B) and PFE($140B) have the same market capitalization . GILD has higher P/E ratio than PFE: GILD (22.97) vs PFE (13.07). GILD YTD gains are higher at: 27.098 vs. PFE (-1.849). PFE has higher annual earnings (EBITDA): 20.2B vs. GILD (11B). PFE has more cash in the bank: 13.2B vs. GILD (5.21B). GILD has less debt than PFE: GILD (24.9B) vs PFE (60.9B). PFE has higher revenues than GILD: PFE (63.8B) vs GILD (28.9B).
GILDPFEGILD / PFE
Capitalization144B140B103%
EBITDA11B20.2B54%
Gain YTD27.098-1.849-1,465%
P/E Ratio22.9713.07176%
Revenue28.9B63.8B45%
Total Cash5.21B13.2B39%
Total Debt24.9B60.9B41%
FUNDAMENTALS RATINGS
GILD vs PFE: Fundamental Ratings
GILD
PFE
OUTLOOK RATING
1..100
6816
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
5
Undervalued
PROFIT vs RISK RATING
1..100
12100
SMR RATING
1..100
2962
PRICE GROWTH RATING
1..100
4955
P/E GROWTH RATING
1..100
9998
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as GILD (16) in the Biotechnology industry. This means that PFE’s stock grew similarly to GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than PFE’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for PFE (62) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than PFE’s over the last 12 months.

GILD's Price Growth Rating (49) in the Biotechnology industry is in the same range as PFE (55) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to PFE’s over the last 12 months.

PFE's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as GILD (99) in the Biotechnology industry. This means that PFE’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDPFE
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
49%
Momentum
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
67%
MACD
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
53%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
54%
Advances
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 8 days ago
57%
Declines
ODDS (%)
Bearish Trend 13 days ago
48%
Bearish Trend 6 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
45%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SRHQ38.54N/A
N/A
SRH U.S. Quality GARP ETF
GUMI50.28N/A
N/A
Goldman Sachs Ultra Shrt Muncpl Inc ETF
AVSF47.23-0.01
-0.03%
Avantis Short-Term Fixed Income ETF
DFUV44.15-0.02
-0.05%
Dimensional US Marketwide Value ETF
BCIL29.75-0.16
-0.54%
Bancreek International Large Cap ETF

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
-0.10%
BMY - GILD
47%
Loosely correlated
+1.09%
GSK - GILD
43%
Loosely correlated
+1.82%
NVS - GILD
40%
Loosely correlated
-0.51%
AMGN - GILD
40%
Loosely correlated
-0.08%
PFE - GILD
38%
Loosely correlated
+0.65%
More